SpaceX's $75B IPO is about to flood Series A/B with $500B

Good morning, founderscrowd enthusiasts. 

SpaceX just pulled off the largest capital deployment event in private markets history.

It also just proved that mega-caps are going to own infrastructure for the next decade. And it signaled where the next wave of venture capital is actually flowing.

We're Jose and Alberto from Founderscrowd.

Here are the three stories that actually matter this week.

TOP NEWS

5 Stocks Already Pricing In the SpaceX IPO

Wall Street isn't waiting for the filing. Five publicly traded companies are already accumulating exposure to SpaceX's core revenue streams — Starlink, Falcon 9, and the defense contracts. We've identified each one, ranked by upside and risk tier. Get the before the listing window closes.

🚀 SPACEX IPO JUST REDISTRIBUTED $500B IN VENTURE CAPITAL

The Signal: SpaceX raised $75 billion Thursday night — the largest IPO in history. But that's not the story. The story is that Founders Fund, Andreessen Horowitz, and Sequoia just got multi-billion-dollar liquidity events. And they're about to redeploy all of it.

SPACE X

The Details:

SpaceX priced at $135 per share and opened at $175 — a 30% first-day pop. The company is now valued at $1.77 trillion, making it the seventh largest U.S. company by market cap (ahead of Tesla). The raise more than doubles Saudi Aramco's 2019 record of $29.4B.

Founders Fund's $600 million bet made from 2004-2010 is now worth $50+ billion. Andreessen Horowitz's position is worth $10+ billion — their single largest return. Sequoia's $2B investment is now worth $20+ billion.

The company lost $4.9B on $18.7B in revenue in 2025. Yet investors just valued it at nearly $2 trillion based on future orbital data centers, Starlink dominance, and a Martian city. Retail investors got 30% of the allocation — triple the normal amount — via Robinhood, Fidelity, and SoFi.

Why It Matters:

This IPO is legally forcing a capital redeployment cascade. Venture funds are obligated to distribute capital to their LPs. Those distributions — $100B+ — will redeploy into Series A/B companies from July through November 2026.

Translation: The next 6 months are the most capital-rich fundraising environment of the year. If you're a founder raising Series A or Series B, September is when the capital hits. If you're raising Seed, August is when tier-one VCs start actively deploying.

But here's what's being missed: the $75B raise proves that mega-caps can deploy capital faster and at larger scale than any venture fund ever could. That brings us to story two.Total capital redeployment potential: $350-550 billion

💰 ORACLE JUST DECLARED WAR ON INFRASTRUCTURE STARTUPS

The Signal: Oracle announced $70 billion in capital spending for fiscal 2027, nearly double their $55.7 billion spend in 2026. They're building data centers for OpenAI, Meta, and every AI company that needs compute. And they're signaling: you can't compete with us.

The Details:

Oracle's capex is increasing 27% year-over-year. Microsoft, Amazon, and Google are all doing the same thing, deploying $50B-$100B annually into infrastructure.

The company is claiming sevenfold better water efficiency than the industry average (2.5B gallons annually for data centers). They're on track to be "water positive" by 2030. And they're just getting started.

But Amazon's water disclosure and Seattle's moratorium on new data center construction reveal the real constraint: physical resources (water, electricity, real estate) are becoming scarce. Only companies that already own these resources can build at scale.

Why It Matters:

The infrastructure wars just shifted from "who builds faster" to "who owns the resources." Mega-caps already have:

• Land rights for data centers

• Long-term electricity contracts

• Water rights (or can build reclamation)

• Regulatory relationships with cities

A startup trying to build a competing data center infrastructure company in 2026 can't. They'll be outspent 100:1 by Oracle, Microsoft, and Amazon.

This is a death knell for venture-scale infrastructure. The only infrastructure startups that survive are those that:

1. Get acquired by a mega-cap for 2-5x revenue (no real upside)

2. Partner strategically with a mega-cap (secondary to their interests)

3. Focus on a niche that mega-caps won't (unlikely, they'll just buy you)

The implication: founders should stop building infrastructure. Founders should start building applications on top of mega-cap infrastructure.

🧬 BIOTECH JUST BECAME THE LAST FRONTIER FOR VENTURE CAPITAL

The Signal: Two separate breakthroughs this week signaled the same thing: capital is moving to the only sector left where venture can still compete and win.

The Details:

Researchers discovered manikomycin — an antibiotic that kills drug-resistant bacteria using a mechanism no other drug has hit before. It came from 75-year-old soil. A compound that's been overlooked for decades, suddenly becomes valuable because of better lab techniques.

Simultaneously, Harvard's David Sinclair announced he's testing SL-100 — a whole-body age-reversal pill — for a $101 million XPrize award. The Saudi-backed prize is betting that whole-body rejuvenation will be solved in the next five years.

Both stories have skeptics (Sinclair's credibility is damaged, the antibiotic doesn't work in humans yet). But the signal is clear: billions of dollars are flowing into longevity companies, biotech startups, and pharmaceutical innovation.

By 2050, drug-resistant infections could kill 1.91 million people annually. The global longevity market could be worth $100 trillion+. These are the largest TAMs in history.

Why It Matters:

Infrastructure is a mega-cap exclusive. Software is commoditized. The only sector where venture capital can still generate 50x+ returns is biotech.

This is high-risk. Regulatory approval takes years. Clinical trials fail. The FDA is unpredictable. But the upside is unlimited.

If you're a founder, biotech is the next frontier. If you're an investor, capital is flowing here. If you're in software or infrastructure, your returns are capped. If you're in biotech, your returns are unlimited (or you fail).

QUICK HITS

Quick Hits

📰 Everything else that mattered this week

Oracle Infrastructure War Escalates — Oracle's $70B capex announcement (nearly double 2026 spending) signals that the infrastructure consolidation is accelerating. Amazon, Microsoft, and Google are all racing to control AI data center capacity. Water and electricity are becoming the real constraints.

DoorDash Voice Ordering Launches — "Ask DoorDash" lets users order via voice, text, or camera. Signal: voice AI is now table stakes for consumer apps. Apps without a voice interface are losing to those with it.

Xiaomi Pivots to Extended-Range EVs — Chinese automaker moving from phones into EVs. Signal: distribution networks enable rapid category expansion. If you have customer access, new markets open fast.

Pokémon GO Military AI Connection — 30 billion location scans from Pokémon GO players just trained military navigation drones. Signal: every consumer app is a data engine. Your user data becomes AI training data worth billions.

Biotech Wave Accelerates — Between superbug discovery and age-reversal pill testing, billions are flowing into longevity and antibiotics. Signal: biotech is the new frontier for venture capital.

José & Alberto's Take

This week proved three things:

One: SpaceX's IPO isn't about SpaceX. It's about $500B+ in venture capital about to redeploy into Series A/B companies. September is your fundraising month.

Two: Oracle's $70B capex announcement isn't about Oracle. It's the death of venture-scale infrastructure. Mega-caps now own infrastructure. You can't compete.

Three: The biotech announcements aren't about superbugs or age-reversal pills. They're about the last frontier for venture capital. Billions flowing in. Winners will be worth trillions.

The playbook changed this week. If you're a founder, you have three paths:

1. Build biotech (highest risk, unlimited upside)

2. Build applications on mega-cap infrastructure (crowded, lower returns)

3. Get acquired by a mega-cap (reasonable returns, clear exit)

If you're an investor, you have three paths:

1. Compete with mega-caps in infrastructure (you'll lose)

2. Bet on apps in a crowded market (lower returns)

3. Bet on biotech early (highest risk, unlimited upside)

Hunt accordingly.

Have a wonderful Saturday :)

Jose & Alberto
Founderscrowd